Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in TPO-RA-Refractory Persistent Thrombocytopenia After Allo-HSCT
NCT07535645Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in Thrombocytopenia, sponsored by Peking University People's Hospital. Started Mar 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07535645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535645.